EGFR and lung adenocarcinoma: A total of 291 EGFR-mutant lung adenocarcinoma patients with brain metastases were enrolled in the study, with 61 patients in the EGFR-TKI alone group and 230 in the EGFR-TKI+craniocerebral radiotherapy group.